| Dr Bassam Aswad, MD | |
|
593 Eddy St, Department Of Pathology-apc 12, Providence, RI 02903-4923 | |
| (401) 444-5165 | |
| (401) 444-8514 |
| Full Name | Dr Bassam Aswad |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255384541 | NPI | - | NPPES |
| 7004470 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | MD8714 (Rhode Island) | Primary |
| Entity Name | Newport Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063632180 PECOS PAC ID: 0042111437 Enrollment ID: O20040422000696 |
News Archive
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies. However, a team of researchers from Wake Forest University Baptist Medical Center, University of Rochester Medical Center and Unity Health System, report that a lack of thorough understanding about the laws governing end-of-life care may be leaving many medical providers with an ethical dilemma and causing some terminally-ill patients considerable, unnecessary pain.
In 2016, 10 times as many Americans as Germans died as a result of drug overdoses, mostly opiates. Three times as many Americans as Germans experienced opioid addiction.
Several companies and research groups have been searching for suitably docking ligands that inhibit the function of this protein. In a research paper recently published to the Springer journal VirusDisease by Surya & Praveen (March 6th, 2021) in silico docking simulations towards 3CLpro have been performed, focusing in particular on natural products obtained from the plant Boerhavia diffusa.
The approach, which is under consideration by state lawmakers, has attracted the interest of conservative governors and legislators in other states who had previously opposed the program's expansion.
› Verified 9 days ago
| Entity Name | University Pathologists, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568640886 PECOS PAC ID: 4981780061 Enrollment ID: O20080529000014 |
News Archive
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies. However, a team of researchers from Wake Forest University Baptist Medical Center, University of Rochester Medical Center and Unity Health System, report that a lack of thorough understanding about the laws governing end-of-life care may be leaving many medical providers with an ethical dilemma and causing some terminally-ill patients considerable, unnecessary pain.
In 2016, 10 times as many Americans as Germans died as a result of drug overdoses, mostly opiates. Three times as many Americans as Germans experienced opioid addiction.
Several companies and research groups have been searching for suitably docking ligands that inhibit the function of this protein. In a research paper recently published to the Springer journal VirusDisease by Surya & Praveen (March 6th, 2021) in silico docking simulations towards 3CLpro have been performed, focusing in particular on natural products obtained from the plant Boerhavia diffusa.
The approach, which is under consideration by state lawmakers, has attracted the interest of conservative governors and legislators in other states who had previously opposed the program's expansion.
› Verified 9 days ago
| Entity Name | Rhode Island Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154537520 PECOS PAC ID: 8921900044 Enrollment ID: O20141017000105 |
News Archive
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies. However, a team of researchers from Wake Forest University Baptist Medical Center, University of Rochester Medical Center and Unity Health System, report that a lack of thorough understanding about the laws governing end-of-life care may be leaving many medical providers with an ethical dilemma and causing some terminally-ill patients considerable, unnecessary pain.
In 2016, 10 times as many Americans as Germans died as a result of drug overdoses, mostly opiates. Three times as many Americans as Germans experienced opioid addiction.
Several companies and research groups have been searching for suitably docking ligands that inhibit the function of this protein. In a research paper recently published to the Springer journal VirusDisease by Surya & Praveen (March 6th, 2021) in silico docking simulations towards 3CLpro have been performed, focusing in particular on natural products obtained from the plant Boerhavia diffusa.
The approach, which is under consideration by state lawmakers, has attracted the interest of conservative governors and legislators in other states who had previously opposed the program's expansion.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bassam Aswad, MD 593 Eddy St, Department Of Pathology-apc 12, Providence, RI 02903-4923 Ph: (401) 444-5165 | Dr Bassam Aswad, MD 593 Eddy St, Department Of Pathology-apc 12, Providence, RI 02903-4923 Ph: (401) 444-5165 |
News Archive
Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the filing of a New Drug Submission (NDS) with Health Canada's Therapeutic Products Directorate (TPD) seeking Canadian approval of intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults with AF for up to 7 days.
When treatment options dwindle or are exhausted, terminally ill-patients often opt for pain management and comfort over life-extending therapies. However, a team of researchers from Wake Forest University Baptist Medical Center, University of Rochester Medical Center and Unity Health System, report that a lack of thorough understanding about the laws governing end-of-life care may be leaving many medical providers with an ethical dilemma and causing some terminally-ill patients considerable, unnecessary pain.
In 2016, 10 times as many Americans as Germans died as a result of drug overdoses, mostly opiates. Three times as many Americans as Germans experienced opioid addiction.
Several companies and research groups have been searching for suitably docking ligands that inhibit the function of this protein. In a research paper recently published to the Springer journal VirusDisease by Surya & Praveen (March 6th, 2021) in silico docking simulations towards 3CLpro have been performed, focusing in particular on natural products obtained from the plant Boerhavia diffusa.
The approach, which is under consideration by state lawmakers, has attracted the interest of conservative governors and legislators in other states who had previously opposed the program's expansion.
› Verified 9 days ago
Dr. Ga Hie Nam, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-5057 Fax: 401-444-8514 | |
N Peter Libbey, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 825 Chalkstone Ave, Roger Williams Medical Center/pathology Dept., Providence, RI 02908 Phone: 401-456-2162 Fax: 401-456-2131 | |
Sara Maleki, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 12, Providence, RI 02903 Phone: 401-444-8515 Fax: 401-444-8514 | |
Mirfrida Geller, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-8450 Fax: 401-444-5088 | |
Dr. Lisa Goldstein, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Department Of Pathology, Providence, RI 02906 Phone: 401-793-4246 Fax: 401-274-5154 | |
Dr. Gladys Telang, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Apc 10, Providence, RI 02903 Phone: 401-444-7959 Fax: 401-444-7144 | |
Xin He, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-4923 |